Association of liver metastases (LM) with survival in NSCLC patients treated with durvalumab (D) in two independent clinical trials.

Authors

Luis Paz-Ares

Luis G. Paz-Ares

Medical Oncology Department, Hospital 12 de Octubre, Madrid, Spain

Luis G. Paz-Ares , Kui Shen , Brandon W. Higgs , Chris Morehouse , Naiyer A. Rizvi , Neil Howard Segal , Xiaoping Jin , Yanan Zheng , Rajesh Narwal , Ashok Kumar Gupta , Phillip A. Dennis , Pralay Mukhopadhyay , Koustubh Ranade

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research,Immunotherapy

Sub Track

Biomarkers and Correlative Studies from Immunotherapy Trials

Clinical Trial Registration Number

NCT02087423 and NCT01693562

Citation

J Clin Oncol 35, 2017 (suppl; abstr 3038)

DOI

10.1200/JCO.2017.35.15_suppl.3038

Abstract #

3038

Poster Bd #

133

Abstract Disclosures

Similar Posters

Poster

2021 Gastrointestinal Cancers Symposium

Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.

Response to PD-1 and PD-L1 based immunotherapy in MSS advanced colorectal cancer is impacted by metastatic disease sites.

First Author: Marwan Fakih

First Author: Edward B. Garon

First Author: Katie Streicher